Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

2 Pediatric Indications Sought for Golimumab

Michele B. Kaufman, PharmD, BCGP  |  June 3, 2020

The FDA is reviewing supplemental Biologics License Applications for golimumab to treat polyarticular JIA and juvenile PsA…

Filed under:Drug Updates Tagged with:FDAGolimumabjuvenile idiopathic arthritis (JIA)Psoriatic ArthritisU.S. Food and Drug Administration (FDA)

Rheum After 5: Dr. Victoria Seligman Helps Create Cambodian Healthcare

Carol Patton  |  May 15, 2020

In 2001, Victoria Seligman, MD, MPH, was vacationing in Vietnam. While traveling by train, she met a student from Yale University who was working on the school’s Cambodian Genocide Program, which documents the atrocities that occurred in Cambodia between 1975 and 1979 under the Khmer Rouge regime. Approximately 1.7 million people—representing 21% of the population—were slaughtered….

Filed under:ProfilesRheum After 5 Tagged with:Dr. Victoria SeligmanHealth Volunteers Overseas

Sentavio / shutterstock.com

Rheumatoid Arthritis Therapy Update: What’s Changed & What’s the Same

Kimberly Retzlaff  |  May 15, 2020

SNOWMASS VILLAGE, COLO.—Current trends in rheumatoid arthritis (RA) therapy are the increased use of newer medication categories, such as Janus kinase (JAK) inhibitors (Jakinibs) and biologics, and the rising costs of treatment. Unchanged is the consistent use of methotrexate as an effective therapy. These topics and more were discussed at the ACR Winter Symposium during…

Filed under:Biologics/DMARDsConditionsRheumatoid Arthritis Tagged with:costsjanus kinase inhibitorMethotrexateWinter Rheumatology Summit

ANCA-Associated Vasculitis Trial Results May Change Standard of Care

Kimberly Retzlaff  |  May 15, 2020

SNOWMASS VILLAGE, COLO.—The study of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is ongoing, and research results should help improve treatment for this patient pop­ulation. Key trials and therapeutic options were discussed at the 2020 ACR Winter Symposium during the session, Update on the Treatment of ANCA-Associated Vasculitis, by Peter A. Merkel, MD, MPH, chief of…

Filed under:ConditionsVasculitis Tagged with:ANCA-Associated VasculitisavacopanWinter Rheumatology Summit

The initial physical examination was significant for a nonblanching, papular rash along the palmar aspects of the hands and digits, periungual erythema, and edema and tenderness of the proximal and distal interphalangeal joints of the hands.

Case Report: A Patient with Clinically Amyotrophic Dermatomyositis & Associated ILD & RA Overlap

Vania Lin, MD, MPH, & Leah Krull, MD  |  May 15, 2020

Clinically amyotrophic dermatomyositis (CADM), a subset of dermatomyositis (DM), is a rare autoimmune disease characterized by typical DM cutaneous findings (e.g., heliotrope rash, Gottron papules, Gottron sign) without evidence of myositis.1 The incidence of DM and CADM is approximately 9.63 per 1 million people and 2.08 per 1 million people, respectively.2 The association with development…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Clinically Amyotrophic Dermatomyositis (CADM)combination therapyinterstitial lung disease (ILD)

Shidlovski / shutterstock.com

Studies Suggest Similar Risks for Biologics vs. Conventional Therapies for Rheumatoid Arthritis

Bryn Nelson, PhD  |  May 15, 2020

Two new studies delving into the relative safety of biologic drugs prescribed for rheumatoid arthritis (RA) have concluded that real-world applications of abatacept and tumor necrosis factor inhibitors (TNFi’s) are comparable to more conventional therapies in their associated risk of serious infections. Triple Therapy One study, in Arthritis Care & Research, found the risk of…

Filed under:ConditionsDrug UpdatesResearch RheumRheumatoid Arthritis Tagged with:abatacepttriple therapytumor necrosis factor inhibitor (TNFi)

The Potential for Telemedicine to Supplement In-Person Care

Elizabeth Park, MD  |  May 15, 2020

Even before I started my rheuma­tology fellowship, I knew it would be a demanding career, diagnosing complex diseases with only a few management options in seriously ill patients. What I didn’t appreciate as much before is how badly we are needed across the country. According to the 2018 outcomes report from the National Resident Matching…

Filed under:Practice SupportTechnology Tagged with:Fellows-in-Trainingtelemedicinetelerheumatology

The COVID-19 Global Rheumatology Alliance: Its Genesis, Development & Goals

Philip C. Robinson, MBChB, PhD, FRACP  |  May 8, 2020

Editor’s note: We are sad to announce that we have learned of the passing of Dr. Philip C. Robinson. We will share more as it becomes available, but in the meantime, we wanted to repost this article he wrote for The Rheumatologist early in the pandemic. Dr. Robinson also took the photo of the full-arc rainbow  below.

Filed under:Practice SupportQuality Assurance/Improvement Tagged with:COVID-19COVID-19 Global Rheumatology Alliance

Adapting Care for Pediatric Patients & Parents During the Pandemic: Q&A with Sangeeta Sule, MD, PhD

Susan Bernstein  |  May 1, 2020

Social distancing and telemedicine are creating unique challenges for pediatric rheumatologists to care for their patients—many of whom are 5 years old or younger. Sangeeta Sule, MD, PhD, discusses how her clinic is adapting…

Filed under:Conditions

The author in her home office.

On Pandemics & Uncertainty: One Rheumatologist’s Story

Belinda Birnbaum, MD  |  April 24, 2020

As the mystery solvers, we are supposed to be comfortable with the unknown, but how does that translate when COVID-19 hits home? A rheumatologist contracts COVID-19.

Filed under:ConditionsOpinionSpeak Out Rheum Tagged with:BirnbaumCOVID-19

  • « Previous Page
  • 1
  • …
  • 34
  • 35
  • 36
  • 37
  • 38
  • …
  • 107
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences